化疗患者近期疗效及无进展生存期影响的临床研究.pdfVIP

通补三升汤对晚期肺鳞癌化疗患者近期疗效及无进展生存期影

响的临床研究

王志光;林丽珠;王三虎;范先基;邢晓娟;张定进;杨子玉

【摘要】ThisstudywasaimedtoinvestigatetheefficacyofTong-BuSan-

Sheng(TBSS)Decoctiontoreducethetoxicityandsideeffectsof

chemotherapy,aswellasprolongprogression-freesurvival(PFS)for

advancedlungsquamouscarcinomapatientswhoreceivedchemotherapy.

Atotalof83lungsquamouscarcinomacasesweredividedintotwo

groupsbypatients’wishes.Thecontrolgroupcontained41caseswere

treatedbythechemotherapyofgemcitabinepluscisplatin(GP).Thetrial

groupcontained42casesweretreatedbychemotherapyplusChinese

herbalmedicineTBSSdecoction.Thetoxicityandsideeffectsof

chemotherapy,aswellasshort-termoutcomewereevaluated.PFSof

patientwasrecorded.Theresultsshowedthattherewerenodifferences

ongranulocytopenia(P=0.115)orshort-termoutcome(P=0.081)for

patientsofbothgroupsafterchemotherapy.Thepercentagesofnausea,

vomitingandthrombocytopeniainthetrialgroupwerelowerthanthatin

thecontrolgroup(P=0.037,P=0.040).ThePFSofpatientsinthetrail

groupwereprolongedcomparedtopatientsinthecontrolgroup(4.31±

0.24VS3.78±0.16month;P=0.043).ItwasconcludedthatChineseherbal

medicineTBSSdecoctioncannotreducegranulocytopeniacausedby

chemotherapy,orimprovethetumorresponserate(RR)ofshort-term

outcome.However,itcanprolongPFS,relievenausea,vomitingand

thrombocytopeniaduringchemotherapy.%目的：研究中药通补三升汤对晚期

肺鳞癌化疗患者毒副反应及肿瘤无进展生存期（Progression-freesurvival，PFS）

的干预作用。方法：选取符合标准的83例晚期肺鳞癌患者，按患者意愿分为治疗

组42例及对照组41例，对照组采用GP方案（吉西他滨+顺铂）化疗，治疗组接

受化疗的同时服用中药通补三升汤。评价两组患者化疗期间毒副反应及近期疗效，

记录患者PFS。结果：两组患者治疗后粒细胞水平降低无差异（P=0.115），两组

患者的近期疗效亦无差异（P=0.081）；治疗组发生恶心呕吐及血小板水平降低的

几率低于对照组（P=0.037、P=0.040），治疗组患者的PFS较对照组患者延长

（4.31±0.24VS3.78±0.16月，P=0.043）。结论：中药通补三升汤不能改善肺

鳞癌患者化疗期间的粒细胞水平降低程度，也不能提高近期有效率（Response

RateRR），但能延长PFS，并对化疗期间的恶心呕吐反